Literature DB >> 6288766

Evaluation of the anticomplement immunofluorescence test for detection of antibody to varicella-zoster virus.

C M Preissner, S P Steinberg, A A Gershon, T F Smith.   

Abstract

The anticomplement immunofluorescence (ACIF) test was compared with complement fixation and fluorescent antibody to membrane antigen procedures for the detection of antibody to varicella-zoster virus. All of 50 sera from pregnant women contained antibody measured by ACIF (titer, greater than or equal to 1:10); only 27 (54%) were positive by complement fixation (P less than 0.01). For 16 paired sera obtained before and after varicella-zoster virus infection and tested by ACIF and fluorescent antibody to membrane antigen, the result agreed in 27 determinations (sensitivity, 94%; specificity, 81%). Of 99 sera submitted for routine determinations of immune status to the virus, 89 showed comparable results for both tests (sensitivity, 92.5%; specificity, 88%). The ACIF test offers a specific and sensitive alternative to the fluorescent antibody to membrane antigen procedure for the detection of antibody to varicella-zoster virus. In addition, the ACIF test is rapid, easy to perform, and uses commercially available reagents.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6288766      PMCID: PMC272363          DOI: 10.1128/jcm.16.2.373-376.1982

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  11 in total

1.  NIH conference. Herpes zoster-varicella infections in immunosuppressed patients.

Authors:  R Dolin; R C Reichman; M H Mazur; R J Whitley
Journal:  Ann Intern Med       Date:  1978-09       Impact factor: 25.391

2.  Antibody to varicella-zoster virus-induced membrane antigen: immunofluorescence assay using monodisperse glutaraldehyde-fixed target cells.

Authors:  J A Zaia; M N Oxman
Journal:  J Infect Dis       Date:  1977-10       Impact factor: 5.226

3.  Evaluation of anti-complement immunofluorescence test in cytomegalovirus infection.

Authors:  N Rao; D T Waruszewski; J A Armstrong; R W Atchison; M Ho
Journal:  J Clin Microbiol       Date:  1977-12       Impact factor: 5.948

4.  Anti-complement immunofluorescence test for antibodies to human cytomegalovirus.

Authors:  J D Kettering; N J Schmidt; D Gallo; E H Lennette
Journal:  J Clin Microbiol       Date:  1977-12       Impact factor: 5.948

5.  Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence.

Authors:  V Williams; A Gershon; P A Brunell
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

6.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

7.  Cryopreservation of virus-infected cells for use in the fluorescent antibody to membrane antigen test.

Authors:  M Fishaut; N Murphy; R Yanagihara; K McIntosh
Journal:  J Clin Microbiol       Date:  1980-06       Impact factor: 5.948

8.  An IgG-Fc receptor induced in cytomegalovirus-infected human fibroblasts.

Authors:  R Keller; R Peitchel; J N Goldman; M Goldman
Journal:  J Immunol       Date:  1976-03       Impact factor: 5.422

9.  Anticomplement immunofluorescence for the titration of antibody to varicella-zoster virus.

Authors:  S Shigeta; M Baba; M Ogata; S Iijima; C Murai
Journal:  Microbiol Immunol       Date:  1981       Impact factor: 1.955

10.  Herpes simplex virus nuclear nonvirion antigens detected by anticomplement immunofluorescence.

Authors:  G Tarro; G G Giordano; A Tripodi; R Cerra; M Di Gioia; A Battista; R Smeraglia
Journal:  Tumori       Date:  1976 Nov-Dec
View more
  6 in total

Review 1.  Immunoserology of infectious diseases.

Authors:  K James
Journal:  Clin Microbiol Rev       Date:  1990-04       Impact factor: 26.132

2.  Evaluation of a multiplex bead immunoassay for determination of immune status to varicella-zoster virus in medical center students and employees.

Authors:  Michael J Loeffelholz; Harry E Prince
Journal:  Clin Vaccine Immunol       Date:  2015-01-14

3.  Comparison of fluorescent-antibody-to-membrane-antigen test, indirect immunofluorescence assay, and a commercial enzyme-linked immunosorbent assay for determination of antibody to varicella-zoster virus.

Authors:  M L Landry; S D Cohen; D R Mayo; C K Fong; W A Andiman
Journal:  J Clin Microbiol       Date:  1987-05       Impact factor: 5.948

4.  Importance of anticomplement immunofluorescence antibody titration for diagnosing varicella-zoster virus infection in Bell's palsy.

Authors:  S Shigeta; M Baba; M Ogata; H Nozaki; A Okuaki; S Nakamura
Journal:  J Clin Pathol       Date:  1986-11       Impact factor: 3.411

5.  Impact and costs of varicella prevention in a university hospital.

Authors:  D J Weber; W A Rutala; C Parham
Journal:  Am J Public Health       Date:  1988-01       Impact factor: 9.308

6.  Primary vaccine failure after 1 dose of varicella vaccine in healthy children.

Authors:  David E Michalik; Sharon P Steinberg; Philip S Larussa; Kathryn M Edwards; Peter F Wright; Ann M Arvin; Haley A Gans; Anne A Gershon
Journal:  J Infect Dis       Date:  2008-04-01       Impact factor: 5.226

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.